Illumina Says Array Sales Are 'Stabilized' Despite Decline in Q1 Chip Revenues

While Illumina's first-quarter array sales were down year over year, the company said that orders for its next-generation genotyping arrays are increasing, and that it is optimistic about the business going forward.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.